Clinical trial
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
NCT01054976 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
- Lead sponsor
- Janssen Korea, Ltd., Korea
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 31, 2006
- Completion date
- February 28, 2009
- Enrollment
- 99 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
alzheimer's disease